» Products and Services » Clinical safety and efficacy profile

Efficacy and safety are two major challenges in a preclinical and clinical development. Anaxomics’ validated predictive technology provides a unique and in-depth analysis of the indications and adverse events of your compounds of interest.

Despite the recent advancements in drug discovery, the attrition rates due to lack of efficacy and safety issues remain high. In vitro and in vivo assays, typically used to evaluate efficacy and safety, are time-consuming, expensive and partially representative of responses in humans.

target_offtarget
To address the urgent need for better methods, Anaxomics offers an innovative solution based on systems biology, the TPMS© technology, for evaluating and predicting safety and efficacy aspects of drugs. We put this service at the disposal of pharmaceutical companies and research centres working in drug development, including preclinical and clinical stages.

TPMS determines the safety and efficacy profile of compounds on the basis of their known and predicted targets, analysing the consequences of their modulation in human physiology. As described in the figure on the right, TPMS considers the interaction of multiple targets and off-targets at the same time, as well as their contribution to any disease or indication.

The Anaxomics Safety&Efficacy Analysis gives insight into the physiological actions of your drug

Safety profile: Is my drug safe? Which adverse events might I expect?

The safety analysis may include the following aspects:

  • Prediction of the potential Adverse Events (AEs) of your drug. This prediction is based in TPMS modelling technology.
    List of Potential Adverse Events

  • Comparison between Life Quality (LQ) scores of your drug and other representatives in the same class. The predicted AEs are converted into a LQ score, based on how the list of predicted AEs affect factors related to the patient wellbeing. This allows ranking the drugs by severity of their AEs profile.
    Comparison between Life Quality (LQ) scores

  • Prioritization of your library of compounds according to their safety profile, including a normalized ranking against other drug representatives in the same class.
    Prioritization of your library of compounds efficacy safety


Efficacy profile: Is my drug effective? How does it compare to other drugs in the market?


  • List of potential indications, prioritized according to the predicted efficacy of the drug against each indication.
    efficacy profile

  • Comparison of your drug with standard of care treatments for any specific indication
    efficacy vs. competition

  • Prioritization of your library of compounds according to their efficacy profile, including a normalized ranking against other drug representatives in the same class
    Prioritization of your library of compounds

The Anaxomics Safety&Efficacy Analysis allows you to:

  • Apply safety and efficacy considerations in the screening of your library of compounds
  • Anticipate and solve drug-related safety and efficacy issues before clinical stages
  • Increase the value of your pipeline for out-licensing, by ensuring that the molecules are safe and effective.
  • Select which products to in-license.
  • Convince investors of the safety and efficacy of your molecules, thus helping to raise investments.